Page 82 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Molecular shift in FLT3 during AML course

Res. 2004;10(4):1326-1332. doi: 10.1200/JCO.23.02474

doi: 10.1158/1078-0432.ccr-0835-03 48. Oduro KA Jr., Spivey T, Moore EM, et al. Clonal dynamics
and relapse risk revealed by high-sensitivity FLT3-internal
46. Warren M, Luthra R, Yin CC, et al. Clinical impact of change tandem duplication detection in acute myeloid leukemia.
of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2024;37(9):100534.
Mod Pathol. 2012;25(10):1405-1412.
doi: 10.1016/j.modpat.2024.100534
doi: 10.1038/modpathol.2012.88
49. Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E.
47. Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as Molecular profile of FLT3-mutated relapsed/refractory
post-transplant maintenance for AML with internal patients with AML in the phase 3 ADMIRAL study of
tandem duplication mutation of FLT3. J Clin Oncol. gilteritinib. Blood Adv. 2022;6(7):2144-2155.
2024;42(15):1766-1775. doi: 10.1182/bloodadvances.2021006489

Volume 9 Issue 3 (2025) 74 doi: 10.36922/EJMO025150101